重要內容提示 廣州白雲山醫藥集團股份有限公司（「本公司」）董事會、監事會及董事、監事、高級管理人員保證本 季度報告內容的真實、準確、完整，不存在虛假記載、誤導性陳述或重大遺漏，並承擔個別和連帶 的法律責任。 本公司負責人李小軍先生、主管會計工作負責人劉菲女士及會計機構負責人吳楚玲女士保證本季度 報告中財務信息的真實、準確、完整。 香港交易及結算所有限公司及香港聯合交易所有限公司對本報告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本報告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司） （H股股份代碼：00874） 2025年第一季度報告 註： (1) 除非另有說明，「本報告期」指本季度初至本季度末3個月期間。 (2) 以上財務報表數據和指標均以合併報表數計算。 2 （二）非經常性損益項目和金額 （一）主要會計數據和財務指標 本報告期 | | | | 比上年同期 | | --- | --- | --- | --- | | 項目 | 本報告期 | 上年同期 | 增減變動幅度 | | | （未經審計） | （未經審計） ...

年報 2024 重要提示 經大信會計師事務所（特殊普通合夥）審計確認：2024年度本集團實現歸屬於本公司股東的合併淨利潤 為人民幣2,835,496,163.51元，以本公司2024年度實現淨利潤人民幣1,114,566,368.85元為基數，提 取10%法定盈餘公積金人民幣111,456,636.89元，加上年初結轉未分配利潤人民幣8,389,265,344.67 元，扣減2023年度及2024年中期的現金紅利合共人民幣1,868,033,800.40元後，公司母公司報表期末 未分配利潤為人民幣7,524,341,276.23元。 經本公司董事會審議，本公司擬以實施權益分派股權登記日登記的總股本為基數分配利潤，向全體股 東每股派發現金紅利0.40元（含稅）。截至2024年12月31日，本公司總股本為1,625,790,949股，以此計 算合計擬派發現金紅利650,316,379.60元，剩餘未分配利潤轉入下次分配。本年度不進行資本公積金 轉增股本。 本次利潤分配方案擬提交本公司股東大會審議通過。 本報告期內，不存在對本集團生產經營產生實質性影響的特別重大風險。本報告已詳細闡述本集團在 生產經營過程中可能面臨 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本摘要的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本摘要全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司） 一、重要提示 經大信會計師事務所（特殊普通合夥）審計確認：2024年度本集團實現歸屬於本公司股 東的合併淨利潤為人民幣2,835,496,163.51元，以本公司2024年度實現淨利潤人民幣 1,114,566,368.85元為基數，提取10%法定盈餘公積金人民幣111,456,636.89元，加上年初 結轉未分配利潤人民幣8,389,265,344.67元，扣減2023年度及2024年中期的現金紅利合共 人民幣1,868,033,800.40元後，公司母公司報表期末未分配利潤為人民幣7,524,341,276.23 元。 在本摘要中，除非文義另有所指，下列詞語具有如下含義： （H股股份代碼：00874） 2024年年度報告摘要 1 1.1 本摘要摘自本公司截至2024年12月31日止的2024年年度報告全文，為全面瞭解本公 司的經營成果、財務狀況及未來發展規 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本報告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本報告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司） （H股股份代碼：0874） 2024年第三季度報告 重要內容提示： 廣州白雲山醫藥集團股份有限公司（「本公司」）董事會（「董事會」）、監事會及董事、監事、高級管理人 員保證季度報告內容的真實、準確、完整，不存在虛假記載、誤導性陳述或重大遺漏，並承擔個別 和連帶的法律責任。 本公司負責人楊軍先生、主管會計工作負責人劉菲女士及會計機構負責人吳楚玲女士保證季度報告 中財務信息的真實、準確、完整。 第三季度財務報表是否經審計 □是 ✔否 季度報告分別以中、英文兩種語言編訂，兩種文本若出現解釋上的歧義時，以中文本為準。 1 一、主要財務數據 註： (1) 「本報告期」指本季度初至本季度末3個月期間，下同。 （一）主要會計數據和財務指標 | --- | --- | --- | --- | --- | |----------------------------------| ...

廣州白雲山医药集团股份有限公司 guangzhou baiyunshan pharmaceutical holdings co. ltd. (於中華人民共和國註冊成立之股份有限公司) (H股股份代碼：00874) 2024 (8888) 工艺出 第四集物馆 重要提示 （一） 本公司董事會、監事會及其董事、監事、高級管理人員保證本半年度報告內容的真實、準確、完整， 不存在虛假記載、誤導性陳述或者重大遺漏，並承擔個別和連帶的法律責任。 （二） 本公司董事出席了第九屆董事會第十四次會議，其中，獨立非執行董事陳亞進先生和孫寶清女士以通 訊方式參加了會議；獨立非執行董事黃民先生未能親自出席本次董事會會議，委託獨立非執行董事黃 龍德先生代為出席並行使表決權；執行董事張春波先生因個人原因缺席本次董事會會議。 （三） 本公司負責人楊軍先生、主管會計工作負責人劉菲女士及會計機構負責人吳楚玲女士聲明：保證本半 年度報告中財務報告的真實、準確、完整。 （四） 經董事會審議的本報告期利潤分配預案或公積金轉增股本預案 經本公司董事會審議，本公司擬以實施權益分派股權登記日登記的總股本為基數分配利潤，向全體股 東每10股派發現金紅利4.0 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本摘要的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本摘要全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司） （H股股份代碼：0874） 1.1 本公司半年度報告摘要摘自本公司截至2024年6月30日止六個月的2024年半年度報告全 文，投資者欲瞭解詳細內容，應當仔細閱讀將刊載於上交所網站(http://www.sse.com.cn)等 中國證監會指定網站和港交所網站(https://www.hkexnews.hk/index_c.htm)上的半年度報告 全文。 1.2 本公司董事會、監事會及其董事、監事、高級管理人員保證本摘要內容的真實、準確、完 整，不存在虛假記載、誤導性陳述或者重大遺漏，並承擔個別和連帶的法律責任。 1.3 本公司董事出席了第九屆董事會第十四次會議，其中，獨立非執行董事陳亞進先生和孫寶 清女士以通訊方式參加了會議；獨立非執行董事黃民先生未能親自出席本次董事會會議， 委託獨立非執行董事黃龍德先生代為出席並行使表決權；執行董事張春波先生因個人原因 缺 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本報告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本報告全部或任何部分內容而產生或因依賴該等內 容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立之股份有限公司） （H股股份代碼：0874） 2024年第一季度報告 重要內容提示 廣州白雲山醫藥集團股份有限公司（「本公司」）董事會（「董事會」）、監事會及董事、監事、高級管理人 員保證本季度報告內容的真實、準確、完整，不存在虛假記載、誤導性陳述或重大遺漏，並承擔個 別和連帶的法律責任。 本公司董事長李楚源先生、財務總監劉菲女士及財務部部長吳楚玲女士保證本季度報告中財務信息 的真實、準確、完整。 第一季度財務報表是否經審計 □是 ✔否 本季度報告分別以中、英文兩種語言編製，兩種文本若出現解釋上的歧義時，以中文本為準。 1 一、主要財務數據 （一）主要會計數據和財務指標 | | | | 本報告期比 上年同期增減 | | --- | --- | --- | --- | | | | | 變動幅度 | | 項目 | | 本報告期 | (%) | | | | （未經審計） | | | ...

Financial Performance - The company achieved a consolidated net profit attributable to shareholders of RMB 4,055,678,691.49 for the year 2023, with a base net profit of RMB 1,684,022,544.74[2] - The company achieved a net profit of CNY 1.8 billion, which is a 15% increase compared to the previous year[18] - The company's operating revenue for 2023 reached RMB 75,515,404 thousand, an increase of 6.68% compared to RMB 70,788,155 thousand in 2022[21] - The total profit for the year was RMB 5,110,498 thousand, reflecting a year-on-year increase of 1.33%[29] - The net profit attributable to shareholders for 2023 was RMB 4,055,679 thousand, reflecting a growth of 2.25% from RMB 3,966,522 thousand in the previous year[21] - The company's total assets of the company at the end of 2023 amounted to RMB 78,586,878 thousand, representing a 5.25% increase from RMB 74,665,299 thousand in 2022[21] - The company's total liabilities at the end of 2023 were RMB 41,909,054 thousand, a slight increase of 2.15% from RMB 41,027,441 thousand in 2022[21] - The return on equity attributable to shareholders decreased to 11.61% in 2023 from 12.37% in 2022, a decline of 0.76 percentage points[22] - The company's net assets attributable to shareholders increased to RMB 34,919,281 thousand in 2023, up by 8.90% from RMB 32,065,125 thousand in 2022[21] - The asset-liability ratio improved to 53.33% in 2023, down from 54.95% in 2022, indicating better financial stability[22] Dividend and Profit Distribution - A cash dividend of RMB 0.749 per share (including tax) is proposed, totaling RMB 1,217,717,420.80, based on a total share capital of 1,625,790,949 shares at the end of 2023[2] - The company plans to submit the profit distribution proposal for approval at the 2023 annual general meeting[2] - The company plans to retain the remaining undistributed profits for future distribution, with no capital reserve fund conversion to share capital for this year[2] Risk Management and Compliance - The company has not identified any significant risks that could materially affect its production and operations during the reporting period[4] - The financial report has been audited by Da Xin Certified Public Accountants, providing a standard unqualified audit opinion[1] - The company has confirmed that there are no non-operational fund occupations by controlling shareholders and related parties[3] - The company has not violated any regulatory decision-making procedures in providing guarantees[3] - The board of directors and senior management have ensured the accuracy and completeness of the financial report[1] Market and Product Development - Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited reported a revenue of CNY 10.5 billion for the fiscal year 2023, representing a year-over-year increase of 12%[18] - User data indicates that the company expanded its customer base by 20%, reaching a total of 5 million active users[18] - The company plans to launch three new products in the next quarter, focusing on innovative drug formulations and enhanced delivery systems[18] - Future guidance estimates a revenue growth of 10-15% for the upcoming fiscal year, driven by new product launches and market expansion strategies[18] - The company is investing CNY 500 million in R&D for new technologies aimed at improving drug efficacy and safety[18] - Market expansion efforts include entering two new provinces in China, projected to increase market share by 5%[18] - The company is exploring potential mergers and acquisitions to enhance its product portfolio and distribution capabilities[18] - The company has received regulatory approval for five new drug registrations, expected to contribute an additional CNY 300 million in revenue[18] Research and Development - The company invested a total of RMB 782 million in R&D during 2023, resulting in 11 production approvals for drugs including hydrochloride dapoxetine tablets[35] - The company has established a comprehensive technology innovation system with 5 national-level R&D institutions and 1 national-level enterprise technology center[69] - The company has established 3 provincial and 1 municipal research platforms, along with 6 national and 10 provincial qualifications in research[35] - The company has a strong talent pool, including 3 Nobel Prize winners and over 100 high-level talents with doctoral degrees[70] - The company applied for 134 patents, including 110 invention patents and 24 utility model patents, and received 89 patent grants, with 67 being invention patents[155] Supply Chain and Operations - A new supply chain strategy is being implemented to reduce costs by 8% over the next year[18] - The procurement model has been unified across subsidiaries to enhance cost efficiency and quality control, particularly for bulk Chinese medicinal materials[50] - The company has established multiple medicinal herb planting bases to ensure quality and control costs[147] - The company has a comprehensive supply chain system, integrating raw material procurement, R&D, production, distribution, and retail[66] Marketing and Sales Strategy - The retail network has expanded to 157 outlets, with 51 designated stores for retail business under the "dual-channel" model[32] - The company has established new subsidiaries in Heilongjiang and Shaoguan, enhancing its sales network across Guangdong Province and the Greater Bay Area[32] - The company has a strong marketing network, serving over tens of thousands of customers across more than 30 provinces, cities, and autonomous regions in China[67] - The company is actively expanding its market presence through strategic brand integration and marketing initiatives[64] Regulatory Environment and Industry Trends - The pharmaceutical manufacturing industry in China saw a revenue decline of 3.7% year-on-year, totaling RMB 252.06 billion, with total profits down 15.1% to RMB 34.73 billion[42] - The company is focusing on enhancing product and technology quality management, completing the establishment of a drug adverse reaction monitoring system[37] - The pharmaceutical industry is experiencing accelerated restructuring and integration, with mergers and acquisitions becoming the mainstream approach characterized by strategic resource complementarity and strong alliances[184] - The company plans to enhance the consistency evaluation of generic drugs to improve production efficiency and reduce costs, while actively participating in national procurement tenders[119] Future Outlook and Strategic Initiatives - The company plans to enhance its capabilities in quality management and innovation in response to the new manufacturing policies issued in January and December 2023[125] - The company aims to improve its operational management capabilities in its medical services sector, enhancing service levels and establishing complementary relationships between its hospitals[190] - The company will continue to strengthen talent management and risk control mechanisms to support sustainable and high-quality development[193] - The company is committed to strengthening its capital operations, including plans for a new three-board listing and establishing venture capital funds to support innovation projects[192]

香港交易及結算所有限公司及香港聯合交易所有限公司對本摘要的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並明確表示，概不對因本摘要全部或任何部份內容而產生或因倚賴該等內容 而引致的任何損失承擔任何責任。 H 0874 2023年年度報告摘要 一、重要提示 - 1 - 1.1 本公司本年度報告摘要摘自本公司截至2023年12月31日止的2023年年度報告全文，為全面 了解本公司的經營成果、財務狀況及未來發展規劃，投資者應當仔細閱讀將刊載於上交所 網站（http://www.sse.com.cn）和港交所網站（http://www.hkex.com.hk）等網站上的年度報告全 文。 1.2 本公司董事會、監事會及董事、監事、高級管理人員保證本摘要內容的真實性、準確 性、完整性，不存在虛假記載、誤導性陳述或重大遺漏，並承擔個別和連帶的法律責任。 1.3 本公司董事出席了第九屆董事會第八次會議，其中，副董事長楊軍先生、獨立非執行董事 陳亞進先生和孫寶清女士以通訊方式出席了會議，獨立非執行董事黃龍德先生未能親自出 席本次董事會會議，委託獨立非執行董事黃民先生代為出席並行使表決權。 1.4 本集團與本公司截至202 ...

Financial Performance - Operating revenue for Q3 2023 reached RMB 18,214,219 thousand, an increase of 3.58% year-on-year[2] - Net profit attributable to shareholders was RMB 980,002 thousand, reflecting a growth of 10.81% compared to the same period last year[2] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 840,145 thousand, with a slight increase of 0.78% year-on-year[2] - The basic earnings per share for Q3 2023 was RMB 0.603, up by 10.81% year-on-year[2] - Total operating revenue for the first three quarters of 2023 reached RMB 58.18 billion, an increase of 6.3% compared to RMB 54.81 billion in the same period of 2022[14] - Operating profit for the first three quarters of 2023 was RMB 4.76 billion, up from RMB 4.46 billion in the same period of 2022, reflecting a growth of 6.6%[15] - Net profit attributable to shareholders of the parent company for the first three quarters of 2023 was RMB 3.79 billion, compared to RMB 3.47 billion in 2022, representing an increase of 9.3%[15] - Basic and diluted earnings per share for the first three quarters of 2023 were both RMB 2.332, up from RMB 2.137 in the same period of 2022[16] - The total comprehensive income attributable to shareholders of the parent company for the first three quarters of 2023 was RMB 3.79 billion, compared to RMB 3.48 billion in 2022, an increase of 8.5%[16] Assets and Liabilities - Total assets at the end of the reporting period amounted to RMB 74,353,331 thousand, a decrease of 0.42% from the end of the previous year[2] - Total assets increased to RMB 74.35 billion in 2023 from RMB 74.67 billion in 2022, indicating a slight decrease of 0.4%[13] - Total liabilities decreased to RMB 37,977,384,691.70 from RMB 41,027,440,697.52, a reduction of 7.5%[11] - The company’s total liabilities and equity amounted to RMB 36.38 billion in 2023, up from RMB 33.64 billion in 2022, reflecting an increase of 8.2%[13] Shareholder Information - Shareholders' equity attributable to the parent company increased to RMB 34,660,070 thousand, representing an increase of 8.09% year-on-year[2] - The company had a total of 91,342 common shareholders at the end of the reporting period[4] - The largest shareholder, Guangzhou Pharmaceutical Group Co., Ltd., holds 45.04% of the shares[5] - The company reported a total of 732,305,103 shares held by Guangzhou Pharmaceutical Group Co., Ltd., the largest shareholder[6] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date was RMB 901,626 thousand, showing a significant decrease of 72.67% year-on-year[4] - Operating cash inflow for the first three quarters of 2023 was RMB 53.47 billion, a slight increase from RMB 52.59 billion in the same period of 2022, representing a growth of 1.68%[17] - Cash outflow from operating activities totaled RMB 52.57 billion in 2023, compared to RMB 49.29 billion in 2022, indicating an increase of 6.56%[18] - Net cash flow from operating activities decreased to RMB 901.63 million in 2023, down 72.66% from RMB 3.30 billion in 2022[18] - Cash inflow from investment activities was RMB 2.36 billion in 2023, significantly higher than RMB 253.22 million in 2022[18] - Net cash flow from investment activities was negative at RMB 2.21 billion in 2023, an improvement from a loss of RMB 5.87 billion in 2022[18] - Cash inflow from financing activities was RMB 10.80 billion in 2023, slightly lower than RMB 11.38 billion in 2022, a decrease of 5.06%[19] - Net cash flow from financing activities turned negative at RMB 916.78 million in 2023, compared to a positive flow of RMB 1.29 billion in 2022[19] - The ending cash and cash equivalents balance as of September 2023 was RMB 18.59 billion, down from RMB 19.73 billion at the end of September 2022, a decrease of 5.78%[19] Current Assets and Receivables - As of September 30, 2023, total current assets amounted to RMB 52,924,980,357.93, a decrease of 7.5% from RMB 57,064,311,513.29 on December 31, 2022[8] - Cash and cash equivalents decreased to RMB 19,873,967,228.77 from RMB 22,499,552,770.75, representing a decline of 11.5%[8] - Accounts receivable increased to RMB 16,521,846,517.80, up 11.2% from RMB 14,857,591,768.49[8] - Total non-current assets reached RMB 21,428,350,404.03, an increase of 21.5% compared to RMB 17,600,987,263.45 at the end of 2022[9] - The total amount of accounts payable rose to RMB 12,620,557,642.25, an increase of 12.7% from RMB 11,200,347,828.21[10] Research and Development - Research and development expenses for the first three quarters of 2023 were RMB 579.48 million, down from RMB 664.39 million in 2022, a decrease of 12.8%[14] - The company has not disclosed any significant new product developments or market expansion strategies during the reporting period[7] Foreign Currency Impact - The company recorded a net foreign currency translation difference of RMB 5.07 million in the first three quarters of 2023, compared to RMB 17.80 million in 2022, indicating a decrease of 71.5%[16] - The impact of exchange rate changes on cash and cash equivalents was positive at RMB 6.75 million in 2023, compared to a negative impact of RMB 876.30 thousand in 2022[19]